Clinical Trial Update: Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses [Phase 1]

View source ↗

Summary

This Phase 1 trial from Imperial College London evaluated immunisation strategies using DNA, MVA, and CN54 gp140 with the GLA-AF adjuvant to maximize antibody r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CN54 gp140 protein vaccine (CN54 gp140 HIV envelope protein)
• DNA plasmid vaccine (DNA vaccine (plasmid))
• GLA-AF adjuvant (GLA-AF adjuvant (glucopyranosyl lipid A in an oil-in-water emulsion))
• Modified Vaccinia Ankara (MVA) vector vaccine (MVA-based HIV vaccine vector)

Snippet

Sponsor: Imperial College London | Conditions: HIV | Phase 1 | Status: COMPLETED